Emendo is a biotechnology company that develops and commercializes gene-editing therapeutics for the treatment of genetic diseases... Read more
Emendo is a biotechnology company that develops and commercializes gene-editing therapeutics for the treatment of genetic diseases... Read more
News
Mar 15, 2024
Pharamceutical Technology
EmendoBio: Anocca signs licensing deal for EmendoBio's gene-editing tech
Mar 15, 2024
MarketScreener
EmendoBio: AnGes : Notice of Business Restructuring at Consolidated Subsidiary
Mar 14, 2024
Contract Pharma
EmendoBio: Anocca & EmendoBio Team Up for Next-Gen Cell Therapy
Mar 14, 2024
MarketScreener
EmendoBio: AnGes : Notice of Business Restructuring at Consolidated Subsidiary
May 17, 2022
FirstWord Pharma
EmendoBio: Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
Dec 23, 2021
FirstWord PHARMA
EmendoBio: Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe Congenital Neutropenia
Dec 09, 2021
MarketScreener
EmendoBio: Emendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition
Dec 09, 2021
firstword pharma
EmendoBio: Emendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition
Dec 21, 2020
Global Legal Chronicle
EmendoBio: AnGes'. $250 Million Acquisition of EmendoBio
Dec 15, 2020
Newyork Citybizlist
Emendo Biotherapeutics: EmendoBio Acquired by AnGes
